Perspective Therapeutics, Inc. has announced the appointment of Paul Lyne, Ph.D., as Chief Science Officer. The Company also announced that Michael K. Schultz, Ph.D., co-founder and the Company’s long-time Chief Science Officer, has transitioned to the role of Senior Scientific Advisor & Co-Founder as part of a planned transition toward retirement.
“It is impossible to overstate the impact Michael Schultz has had on Perspective,” said Thijs Spoor, Perspective’s CEO. “Together with co-founder Dr. Frances Johnson, Michael helped lay the scientific groundwork that ultimately led to the creation of the Company, and his leadership, scientific vision, and passion for discovery have touched nearly every aspect of our progress. As he continues in his advisory role, we are deeply grateful that his insight and experience will continue to inform our journey as we advance our early pipeline, scale our manufacturing capabilities, and prepare for late-phase clinical development of our lead program.”
Spoor continued, “We are also excited to welcome Paul Lyne, whose exceptional experience leading oncology research organizations, building high-performing scientific teams, and advancing innovative therapies will help accelerate our scientific strategy and position us for the opportunities ahead.”
Dr. Schultz said, “When Frances and I founded this company, we believed we could build something that would make a meaningful difference for patients with cancer. Seeing that vision evolve into Perspective’s robust scientific platform and clinical pipeline has been incredibly rewarding. I’m proud of everything our team has accomplished. As Perspective moves into its next phase, it is in very good hands. I look forward to continuing to contribute as Senior Scientific Advisor while cheering on the next phase of Perspective’s growth.”
Dr. Lyne joins Perspective with more than 25 years of pharmaceutical and biotechnology industry experience spanning target discovery, drug discovery, early clinical development, portfolio strategy, and organizational leadership. Most recently, he served as Senior Vice President and Head of Oncology Research at Merck KGaA, where he led a global research organization spanning cancer cell signaling, immuno-oncology, and antibody-drug conjugates. Throughout his career, Dr. Lyne has helped advance more than 30 oncology programs into clinical development and contributed to multiple approved cancer medicines. He has also led external innovation initiatives and built high-performing scientific organizations focused on translating breakthrough science into transformative therapies for patients.
"I am very pleased to join Perspective at such an important time in the Company's evolution," said Dr. Lyne. "Perspective has built the most differentiated radiopharmaceutical platform in the industry, with tremendous potential to advance the next generation of precision oncology therapies. I look forward to working with Thijs and this talented team as we continue advancing our pipeline in areas of high unmet need."